person · Reporting owner
Anderson Robert Eugene Jr
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FILANA THERAPEUTICS, INC.SAVA · Entity 7294 | Director | November 24, 2025 | November 25, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FILANA THERAPEUTICS, INC.
Report date November 24, 2025 · Filed November 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,600 |
Reported balance
After 2025-11-24 transaction · row 1
1 source rowRow 1 · 2025-11-24 · Purchase · Acquired 8,600 · Balance 8,600 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 24, 2025 Filed Nov 25, 2025 21:06 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | PurchaseCommon Stock | 8,600 | $2.90 | $24,940.00 |
DisclosureSEC source: 0001437749-25-036321 · rdgdoc.xml · nonDerivative · entry 1 Anderson Robert Eugene Jr · CIK 0002001911 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,600 Read SEC document |
| May 23, 2025 Filed May 27, 2025 20:26 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 26,500 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001437749-25-018505 · rdgdoc.xml · derivative · entry 1 Anderson Robert Eugene Jr · CIK 0002001911 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,500 Underlying: Common Stock · 26,500 shares Expires 2035-05-23 F1 · derivative.exercise_date: Form 4 represents grant pursuant to the Amended Non-employee Director Compensation Program approved by stockholders on May 23, 2025. Stock options vest over a one (1) year period at a rate of 1/12 per month. Read SEC document |
| May 09, 2024 Filed May 13, 2024 20:13 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $21.11 | $0.00 |
DisclosureSEC source: 0001437749-24-016241 · rdgdoc.xml · derivative · entry 1 Anderson Robert Eugene Jr · CIK 0002001911 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-05-09 F1 · derivative.exercise_date: Form 4 represents grant pursuant to the Non-employee Director Compensation Program approved by stockholders on May 4, 2023. Stock options vest over a one (1) year period at a rate of 1/12 per month. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 21:55 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $21.71 | $0.00 |
DisclosureSEC source: 0001437749-23-033890 · rdgdoc.xml · derivative · entry 1 Anderson Robert Eugene Jr · CIK 0002001911 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-12-06 F1 · derivative.exercise_date: The stock option vests over three (3) years at a rate of 1/36th each month. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.